Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Year: 2024
Type: article
Source: Blood Advances
Authors: Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby A. Eyre, Damien Roos-Weil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S. Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp B. Staber
Institutions: University Hospital Cologne, Leipzig University, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, University of Trieste, Azienda sanitaria universitaria Giuliano Isontina, Mayo Clinic, University Medical Center Groningen, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Máxima Medisch Centrum, Dana-Farber Cancer Institute, Churchill Hospital, Oxford University Hospitals NHS Trust, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, The University of Texas MD Anderson Cancer Center, AbbVie (United States), Centre de physique des particules de Marseille, University of Vienna, Medical University of Vienna
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, Alexion Pharmaceuticals, Celgene, Jazz Pharmaceuticals, TG Therapeutics, Astex Pharmaceuticals, MEI Pharma, BeiGene, Incyte, Argenx, Iterion Therapeutics, Ascentage Pharma, Astellas Pharma, Swedish Orphan Biovitrum, Grifols, Genentech, Pharmacyclics, Loxo Oncology, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4390660983